Vir Biotechnology, Inc. — 2022 Form 10-K Summary
Business context and reporting period. Vir is a commercial-stage immunology company developing therapies and vaccines for infectious diseases. This annual report covers the fiscal year ended December 31, 2022; the financial figures below are full-year results, not standalone fourth-quarter results. Its only marketed product was sotrovimab (Xevudy), commercialized with GSK, alongside a pipeline focused on HBV, HDV, influenza, COVID-19 and HIV.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $1,615.8 million | $1,095.4 million |
| Cost of revenue | $146.3 million | $65.9 million |
| Research and development | $474.6 million | $448.0 million |
| Selling, general and administrative | $161.8 million | $160.8 million |
| Operating income | $833.1 million | $420.8 million |
| Net income | $515.8 million | $528.6 million |
| Net income per diluted share | $3.83 | $3.96 |
| Operating cash flow | $1,663.3 million | $(47.6) million |
- Revenue less cost of revenue was approximately 90.9% of revenue; operating margin was 51.6% and net margin 31.9%. These figures reflect the company’s collaboration revenue and do not represent product-level profitability.
- At year-end, cash, cash equivalents and investments totaled approximately $2.4 billion, including $848.6 million of cash and cash equivalents, $1.5 billion of short-term investments and $23.9 million of long-term investments.
- Current assets were $2.52 billion and current liabilities $511.0 million. The company reported no debt outstanding. Noncurrent operating lease liabilities were $123.8 million; total expected lease payments were $175.0 million through 2033.
- Management said available cash, cash equivalents and investments were expected to fund current operating plans for at least 12 months from the financial-statement issuance date, while noting that plans and funding needs may change.
Material changes versus the prior year
- Revenue rose 47.5%, primarily from the GSK sotrovimab profit share. Collaboration revenue was $1.505 billion, compared with $917.2 million in 2021.
- Reported 2022 sotrovimab profit-share revenue included a $369.7 million constraint for anticipated future manufacturing-cost adjustments tied to excess supply and unused binding capacity. Before that constraint, the disclosed profit-sharing amount was $1.875 billion.
- Operating income nearly doubled, but net income declined 2.4% to $515.8 million. The change reflected, among other items, a $111.1 million unrealized loss on the Brii Bio equity investment in 2022 versus a $138.0 million gain in 2021, and a higher income-tax provision ($238.4 million versus $21.2 million).
- Operating cash flow moved to $1.663 billion from cash used of $47.6 million, principally reflecting sotrovimab-related cash collections and a reduction in collaboration receivables. Investing cash outflow increased to $1.193 billion, largely from purchases of investments and property and equipment.
- Year-end cash, cash equivalents and investments increased from approximately $1.34 billion in 2021 to $2.39 billion in 2022. The Brii Bio investment’s fair value fell to $31.9 million from $143.1 million.
Outlook, management commentary and key risks
- Sotrovimab exposure: The FDA had excluded sotrovimab use in all U.S. regions by 2022 because of variant susceptibility. The product remained authorized or approved in more than 40 countries, but foreign restrictions, variant changes and uncertain government procurement could reduce sales. Vir and GSK said they did not plan to file a U.S. BLA at that time.
- Pipeline outlook: Management anticipated 2023 data from HBV combination studies, the influenza VIR-2482 trials and HDV SOLSTICE; initial PREVAIL HBV data were expected in the first half of 2024. These are stated expectations, not assured outcomes. VIR-1111’s first two cohorts showed no sustained HIV insert-specific T-cell responses; higher-dose cohort data were expected in the first half of 2023.
- Safety and development: In February 2023, nivolumab was discontinued from certain HBV combination cohorts following immune-related adverse events consistent with the drug class. Clinical results remain preliminary and may change; trials may fail, be delayed or require additional studies.
- Costs and contingencies: The $369.7 million sotrovimab revenue constraint reflects uncertain future manufacturing adjustments and demand. The company also relies on third-party manufacturers, has collaboration and license milestone and royalty obligations, and expects $175.0 million of lease payments through 2033. Potential BARDA funding of up to approximately $1.0 billion is contingent on options and further development; the base period included approximately $55 million in government funding for VIR-2482-related costs.
- Leadership: CEO George Scangos announced his retirement effective April 3, 2023, with Marianne De Backer named as successor. CFO Howard Horn was to step down effective March 27, 2023, with Sung Lee appointed as successor.
- Other risks: The company expects significant ongoing R&D spending and possible future losses; funding access, clinical and regulatory outcomes, competition, intellectual-property protection, supply continuity, cybersecurity and reimbursement remain material risks. The filing reported no material legal proceedings. Ernst & Young issued unqualified opinions on the financial statements and internal control; a previously identified material weakness involving review of the sotrovimab revenue constraint was reported remediated in the fourth quarter.
Important facts for investors to verify
- How sotrovimab authorizations, variant susceptibility, procurement and GSK-reported manufacturing charges affect future revenue and the $369.7 million constraint.
- Whether Vir’s reported cash and investments remain sufficient as pipeline spending, manufacturing commitments and collaboration costs evolve.
- Upcoming clinical-trial results, enrollment progress and safety updates—especially for VIR-2218, VIR-3434, VIR-2482 and the discontinued nivolumab cohorts.
- Leadership transition execution, collaboration rights and potential milestone, royalty and lease obligations.
- Whether the stated cash runway and pipeline timelines remain valid; the filing does not provide specific revenue or earnings guidance.